Clinical trial
The Hemopexin-Apolipoprotein B Product: A Novel Biomarker Integrating Oxidative Stress and Lipid Metabolism for Coronary Artery Disease Risk Stratification
NCT07126132 is registered in ClinicalTrials.gov with Shiyan City Renmin Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Hemopexin-Apolipoprotein B Product: A Novel Biomarker Integrating Oxidative Stress and Lipid Metabolism for Coronary Artery Disease Risk Stratification
- Lead sponsor
- Shiyan City Renmin Hospital
- Phase
- Observational
- Overall status
- Completed
- Start date
- January 1, 2019
- Completion date
- December 31, 2023
- Enrollment
- 460 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.